These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 2598972)
21. Comparison between serum isonicotinic acid hydrazide (INH) levels and urinary sulfadimidine (sulfamethazine) acetylation as predictors of INH acetylator status. Seth V; Seth SD; Beotra A; Singh U Dev Pharmacol Ther; 1988; 11(1):32-6. PubMed ID: 3383719 [TBL] [Abstract][Full Text] [Related]
22. Kinetic discrimination of three sulfamethazine acetylation phenotypes. Chapron DJ; Kramer PA; Mercik SA Clin Pharmacol Ther; 1980 Jan; 27(1):104-13. PubMed ID: 7351110 [TBL] [Abstract][Full Text] [Related]
23. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Tang BK; Kadar D; Qian L; Iriah J; Yip J; Kalow W Clin Pharmacol Ther; 1991 Jun; 49(6):648-57. PubMed ID: 2060254 [TBL] [Abstract][Full Text] [Related]
25. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis]. Ellard GA Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358 [TBL] [Abstract][Full Text] [Related]
26. N-acetylation pharmacogenetics. Michaelis-Menten constants for arylamine drugs as predictors of their N-acetylation rates in vivo. Andres HH; Weber WW Drug Metab Dispos; 1986; 14(4):382-5. PubMed ID: 2873982 [TBL] [Abstract][Full Text] [Related]
31. An assessment of acetylator polymorphism and its relevance in Papua New Guinea. Hombhanje F P N G Med J; 1990 Jun; 33(2):107-10. PubMed ID: 2238823 [TBL] [Abstract][Full Text] [Related]
32. Acetylator phenotype and the antihypertensive response to hydralazine. Jounela AJ; Pasanen M; Mattila MJ Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859 [TBL] [Abstract][Full Text] [Related]
33. The association of the slow acetylator phenotype with bladder cancer. Evans DA; Eze LC; Whibley EJ J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762 [TBL] [Abstract][Full Text] [Related]
34. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Welfare MR; Cooper J; Bassendine MF; Daly AK Carcinogenesis; 1997 Jul; 18(7):1351-4. PubMed ID: 9230278 [TBL] [Abstract][Full Text] [Related]
35. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Clark DW Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977 [TBL] [Abstract][Full Text] [Related]
36. Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine. Zysset T; Peretti E Eur J Clin Pharmacol; 1986; 30(4):463-6. PubMed ID: 3743623 [TBL] [Abstract][Full Text] [Related]
37. Possible optimization of sulphadimidine dosage for acetylator phenotyping. Hombhanje F Jpn J Pharmacol; 1991 Aug; 56(4):531-4. PubMed ID: 1744992 [TBL] [Abstract][Full Text] [Related]
39. Hepatic acetylator phenotype in bladder cancer patients. Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of the sulphadimidine acetylator phenotyping test in patients with reduced renal function. Hall S Acta Med Scand; 1981; 209(6):505-7. PubMed ID: 7257867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]